Literature DB >> 21209395

Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer.

Fritcher Emily G Barr1, Amy C Degnim, Lynn C Hartmann, Derek C Radisky, Judy C Boughey, Stephanie S Anderson, Robert A Vierkant, Marlene H Frost, Daniel W Visscher, Carol Reynolds.   

Abstract

Estrogen receptor (ER) is expressed in normal and malignant breast epithelium, and expression levels have been found to increase with age in normal breast epithelium but not in atypical hyperplasia (AH) and carcinoma in situ. Here we assess ER expression in AH and its association with later breast cancer. ER expression was assessed immunohistochemically in archival sections from 246 women with AH who had open benign breast biopsy from 1967 to 1991. The ACIS III (Dako) was utilized to calculate ER expression in all atypical foci. Using multivariate linear regression, we examined associations of ER expression with age at biopsy, indication for biopsy, type of atypia, number of atypical foci, involution status, and family history. Breast cancer risk across levels of ER expression was also assessed compared with the Iowa SEER control population. Among 246 women, 87 (35%) had atypical ductal hyperplasia (ADH), 141 (57%) had atypical lobular hyperplasia (ALH), and 18 (7%) had both. Forty-nine (20%) developed breast cancer (median follow-up of 14.4 years). Multivariate analysis indicated that type of atypia and age at diagnosis were significantly associated with ER percent staining and intensity (P < 0.05). ER expression was increased in women with ADH and/or those over age 55. ER expression did not significantly impact breast cancer risk in patients diagnosed with atypia. We found increasing ER expression in AH with increasing age. ER expression in AH does not further discriminate breast cancer risk in women with atypia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21209395      PMCID: PMC3049965          DOI: 10.1158/1940-6207.CAPR-10-0242

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  27 in total

1.  Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard.

Authors:  S Wang; M H Saboorian; E P Frenkel; B B Haley; M T Siddiqui; S Gokaslan; F H Wians; L Hynan; R Ashfaq
Journal:  Am J Clin Pathol       Date:  2001-10       Impact factor: 2.493

Review 2.  Histological and biological evolution of human premalignant breast disease.

Authors:  D C Allred; S K Mohsin; S A Fuqua
Journal:  Endocr Relat Cancer       Date:  2001-03       Impact factor: 5.678

3.  Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia.

Authors:  D L Page; L W Rogers
Journal:  Hum Pathol       Date:  1992-10       Impact factor: 3.466

4.  Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy.

Authors:  Kenneth Bloom; Douglas Harrington
Journal:  Am J Clin Pathol       Date:  2004-05       Impact factor: 2.493

5.  Atypical hyperplastic lesions of the female breast. A long-term follow-up study.

Authors:  D L Page; W D Dupont; L W Rogers; M S Rados
Journal:  Cancer       Date:  1985-06-01       Impact factor: 6.860

6.  Estrogen and progesterone receptors in the normal female breast.

Authors:  D Ricketts; L Turnbull; G Ryall; R Bakhshi; N S Rawson; J C Gazet; C Nolan; R C Coombes
Journal:  Cancer Res       Date:  1991-04-01       Impact factor: 12.701

7.  Estrogen receptor values in patients with benign breast disease.

Authors:  J C Allegra; M E Lippman; L Green; A Barlock; R Simon; E B Thompson; K K Huff; W Griffin
Journal:  Cancer       Date:  1979-07       Impact factor: 6.860

8.  Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue.

Authors:  O W Petersen; P E Høyer; B van Deurs
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

9.  A prospective study of benign breast disease and the risk of breast cancer.

Authors:  S J London; J L Connolly; S J Schnitt; G A Colditz
Journal:  JAMA       Date:  1992-02-19       Impact factor: 56.272

10.  Risk factors for breast cancer in women with proliferative breast disease.

Authors:  W D Dupont; D L Page
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

View more
  14 in total

Review 1.  Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.

Authors:  David K Lung; Rebecca M Reese; Elaine T Alarid
Journal:  Horm Cancer       Date:  2020-06-26       Impact factor: 3.869

2.  ERβ expression and breast cancer risk prediction for women with atypias.

Authors:  Tina J Hieken; Jodi M Carter; John R Hawse; Tanya L Hoskin; Melanie Bois; Marlene Frost; Lynn C Hartmann; Derek C Radisky; Daniel W Visscher; Amy C Degnim
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

3.  Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.

Authors:  Katherine D Crew
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

4.  p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.

Authors:  Derek C Radisky; Marta Santisteban; Hal K Berman; Mona L Gauthier; Marlene H Frost; Carol A Reynolds; Robert A Vierkant; V Shane Pankratz; Daniel W Visscher; Thea D Tlsty; Lynn C Hartmann
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-15

5.  Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study.

Authors:  Lynn C Hartmann; Derek C Radisky; Marlene H Frost; Richard J Santen; Robert A Vierkant; Lorelle L Benetti; Yaman Tarabishy; Karthik Ghosh; Daniel W Visscher; Amy C Degnim
Journal:  Cancer Prev Res (Phila)       Date:  2014-01-30

6.  Atypical hyperplasia of the breast--risk assessment and management options.

Authors:  Lynn C Hartmann; Amy C Degnim; Richard J Santen; William D Dupont; Karthik Ghosh
Journal:  N Engl J Med       Date:  2015-01-01       Impact factor: 91.245

7.  Aromatase expression in atypical ductal hyperplasia in women.

Authors:  R J Santen; D C Radisky; A Degnim; M H Frost; C M Vachon; K Ghosh; F Guestini; K M McNamara; H Sasano
Journal:  Breast Cancer Res Treat       Date:  2017-03-23       Impact factor: 4.624

8.  Expression pattern and methylation of estrogen receptor α in breast intraductal proliferative lesions.

Authors:  Xiaoyun Mao; Zhen Qiao; Chuifeng Fan; Ayao Guo; Xinmiao Yu; Feng Jin
Journal:  Oncol Rep       Date:  2016-08-01       Impact factor: 3.906

9.  Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case-control study.

Authors:  Margarita Posso; Josep M Corominas; Laia Serrano; Marta Román; Isabel Torá-Rocamora; Laia Domingo; Anabel Romero; María Jesús Quintana; María Vernet-Tomas; Marisa Baré; Carmen Vidal; Mar Sánchez; Francina Saladié; Carmen Natal; Joana Ferrer; Sònia Servitja; María Sala; Xavier Castells
Journal:  Cancer Med       Date:  2017-05-04       Impact factor: 4.452

10.  How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?

Authors:  Katherine D Crew; Kathy S Albain; Dawn L Hershman; Joseph M Unger; Shelly S Lo
Journal:  NPJ Breast Cancer       Date:  2017-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.